Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03899090
Other study ID # Float R34
Secondary ID R34AT009889
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 8, 2019
Est. completion date May 31, 2024

Study information

Verified date October 2023
Source Laureate Institute for Brain Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 75 participants with clinical anxiety and depression.


Description:

Anxiety and depression are the two most common psychiatric conditions, affecting over a quarter of the population, and representing the leading cause of disability, worldwide. More than three-quarters of patients never receive treatment, and recent meta-analyses and large-scale clinical trials suggest that only about half of patients improve with treatment, with substantially poorer outcomes and adherence in patients with comorbid anxiety and depression. Given the insufficient treatment response and adherence to currently available therapies, it is important to explore novel ways of helping patients with anxiety and depression. Floatation-REST (Reduced Environmental Stimulation Therapy) is a relatively unexplored mind-body intervention for naturally reducing physiological stress by attenuating exteroceptive sensory input to the nervous system through the act of floating supine in a pool of water saturated with Epsom salt (magnesium sulfate). Over the past decade, floating has witnessed a rapid rise in popularity, with hundreds of recreational float centers opening across America. Despite the surge in public interest and consumption, there has been little research investigation Floatation-REST, especially in clinical populations. The investigators recently completed several pilot studies in patients with comorbid anxiety and depression showing that a single float session was capable of inducing a large short-term anxiolytic and antidepressant response accompanied by a substantial improvement in mood and subjective well-being. This proposal aims to follow-up on these promising preliminary findings by investigating the feasibility, tolerability, and safety of undergoing multiple sessions of Floatation-REST or an active comparison condition in 75 participants with clinical anxiety and depression. A subset of these participants will have the opportunity to select their preference with regard to float duration and frequency, providing important information for optimizing the "dose" in future trials. Since this study is aimed at examining feasibility, tolerability, and safety, the primary endpoint is adherence (as a proxy of feasibility), and the secondary outcome measures are dropout rate (as a proxy for tolerability) and adverse effects (as a proxy for safety). An exploratory aim examines the magnitude and duration of the anxiolytic and antidepressant effects of Floatation-REST at both short-term (up to 48 hours) and long-term (up to 6 months) intervals, providing an initial indication for whether any beneficial effects are sustained beyond the float experience. The results of this early phase clinical trials will help optimize the design of a future efficacy study exploring the long-term effects of Floatation-REST.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 75
Est. completion date May 31, 2024
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. High level of acute anxiety (OASIS score = 6) 2. High anxiety sensitivity (ASI-3 total score = 24) 3. If taking medication or receiving psychotherapy, must be stably undergoing treatment prior to participation (defined as having taken the medication or been in therapy for 8 weeks or longer). If taking a benzodiazepine or opioid, must be willing to abstain within 24 hours of a float session (daily users will be excluded from the study). 4. No prior Floatation-REST experience or a minimum of 1 year since previous float session 5. Seeking treatment for their anxiety/depression and willing to complete the study Exclusion Criteria: 1. History of Bipolar Disorder, Schizophrenia spectrum or other psychotic disorders 2. Current Eating Disorder (anorexia/bulimia nervosa) 3. Current Substance Use Disorder = moderate. Tobacco and Caffeine Use is allowed. Must be willing to abstain from all other substances within 24 hours of a float session. 4. Active suicidality with plan/intent 5. History of a neurological condition (e.g., epilepsy) or any other medical condition that could interfere with the protocol 6. Any skin conditions or open wounds that could cause pain when exposed to saltwater 7. Uncomfortable being in water 8. Positive pregnancy test 9. Acutely intoxicated day of floating (determined via positive urine drug screen or breathalyzer)

Study Design


Intervention

Behavioral:
Float pool
Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
Float chair
Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.

Locations

Country Name City State
United States Laureate Institute for Brain Research Tulsa Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Laureate Institute for Brain Research, Inc. National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood concentration (pg/mL) of proinflammatory cytokines (IFN-?, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-a) At each time point, 10 cytokines will be measured in the blood as well as in response to a potent immune stressor (endotoxin) Blood samples collected at 3 time points: beginning of intervention (baseline), end of intervention (6-9 weeks after baseline), and at 6-week follow-up (12-15 weeks after baseline).
Primary Adherence As a proxy of feasibility, adherence for each subject = (# of sessions completed)/6.
All subjects (in all arms of the study) are given up to 3 opportunities to reschedule missed appointments, after which they are withdrawn from the study.
Over 6-9 week period of intervention (up to 12 weeks for preferred pool arm)
Secondary Dropout rate As a proxy for tolerability, dropout rate for each arm = (# of subjects who are withdrawn from the study)/25.
All subjects (in all arms of the study) are given up to 3 opportunities to reschedule missed appointments, after which they are withdrawn from the study.
Over 6-9 week period of intervention (up to 12 weeks for preferred pool arm)
Secondary Adverse effects As a proxy of safety, adverse effects for each subject = # of instances during the study when a subject reports elevations above mild for any negative effects on the side effect checklist (administered after each float session) Over 6-9 week period of intervention (up to 12 weeks for preferred pool arm)
Secondary Psychological Distress on the Brief Symptom Inventory-18 Total Score on the Brief Symptom Inventory-18 [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Anxiety on the Brief Symptom Inventory-18 Anxiety subscale [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Depression on the Brief Symptom Inventory-18 Depression subscale [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Somatization on the Brief Symptom Inventory-18 Somatization subscale [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Anxiety on the clinician-rated Hamilton Anxiety Rating Scale (HAM-A) Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Depression on the clinician-rated Montgomery Åsberg Rating Scale (MADRS) Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Disability on the Sheehan Disability Scale Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Anxiety remission Percent of individuals by condition (chair, pool, pool-preferred) who have a HAM-A score of = 7 An average of 6 weeks after the final float session
Secondary Anxiety responder Percent of individuals by condition (chair, pool, pool-preferred) who show a 50% reduction on HAM-A or Overall Anxiety Severity and Impairment Scale (OASIS) Through study completion, an average of 6 months after the final float session
Secondary Depression remission Percent of individuals by condition (chair, pool, pool-preferred) who have a MADRS score of = 9 An average of 6 weeks after the final float session
Secondary Depression responder Percent of individuals by condition (chair, pool, pool-preferred) who show a 50% reduction on MADRS or Patient Health Questionnaire-9 (PHQ-9) Through study completion, an average of 6 months after the final float session
Secondary Depression on the Patient Health Questionnaire-9 (PHQ-9) Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Anxiety on the Overall Anxiety Severity and Impairment Scale (OASIS) Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Anxiety Sensitivity on the Anxiety Sensitivity Index-3R (ASI-3R) Total score [Average change pre to post-intervention] Through study completion, an average of 6 months after the final float session
Secondary Positive Affect on the Positive and Negative Affect Schedule-X (PANAS-X) Average of Positive Affect rating change scores from pre-to-post float across all six floats for each condition (chair, pool, pool-preferred) Through completion of the final float session
Secondary Negative Affect on the Positive and Negative Affect Schedule-X (PANAS-X) Average of Negative Affect rating change scores from pre-to-post float across all six floats for each condition (chair, pool, pool-preferred) Through completion of the final float session
Secondary Serenity on the Positive and Negative Affect Schedule-X (PANAS-X) Average of Serenity rating change scores from pre-to-post float across all six floats for each condition (chair, pool, pool-preferred) Through completion of the final float session
Secondary State Anxiety on the State Trait Anxiety Inventory (STAI) Average of STAI State Anxiety rating change scores from pre-to-post float across all six floats for each condition (chair, pool, pool-preferred) Through completion of the final float session
Secondary Muscle Tension rating on the Visual Analog Scale (VAS) Average of VAS muscle tension rating change scores from pre-to-post float all six floats for each condition (chair, pool, pool-preferred) Through completion of the final float session
Secondary Pain on the Wong-Baker Pain Scale (WBPS) Average of WBPS rating change from pre-to-post float across all six floats for each condition Through completion of the final float session
Secondary Trait Anxiety on the State Trait Anxiety Inventory Average of STAI Trait Anxiety rating change scores from pre-to-post float across all six floats for each condition (chair, pool, pool-preferred) Through study completion, an average of 6 months after the final float session
Secondary Cardiac interoceptive accuracy Average of Beat-to-squeeze consistency on cardiac interoception task Through completion of the final float session
Secondary Heartbeat perception rating Average of heartbeat intensity, task difficulty, and task accuracy ratings Through completion of the final float session
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A